Evaluation the effect of allium hirtifolium in the treatment of hyperlipidemia

Evaluation the effect of allium hirtifolium on serum lipid profile in adult patients with hyperlipidemia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150721023282N7

Enrollment

Registered

2020-01-03

Start date

2018-11-22

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia. Hyperlipidemia, unspecified

Interventions

Intervention 1: Drug group: 500-mg oral capsules of Allium, twice daily, for 6 weeks. Intervention 2: Placebo group: 500-mg oral capsules of placebo, twice daily, for 6 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age of more than 18 years Serum level of LDL between 100 to 160 mg/dL Having less than 2 cardiovascular risk factors

Exclusion criteria

Exclusion criteria: Cardiac stable angina Diabetes mellitus Diseases affecting level of serum lipids Use of drugs affecting level of serum lipids

Design outcomes

Primary

Measure	Time frame
Serum level of triglycerides. Timepoint: Before the intervention and the end of intervention (6 weeks after the start of intervention). Method of measurement: Blood test.;Serum level of LDL. Timepoint: Before the intervention and the end of intervention (6 weeks after the start of intervention). Method of measurement: Blood test.;Serum level of HDL. Timepoint: Before the intervention and the end of intervention (6 weeks after the start of intervention). Method of measurement: Blood test.;Serum level of total cholesterol. Timepoint: Before the intervention and the end of intervention (6 weeks after the start of intervention). Method of measurement: Blood test.	—

Measure

Time frame

Serum level of triglycerides. Timepoint: Before the intervention and the end of intervention (6 weeks after the start of intervention). Method of measurement: Blood test.;Serum level of LDL. Timepoint: Before the intervention and the end of intervention (6 weeks after the start of intervention). Method of measurement: Blood test.;Serum level of HDL. Timepoint: Before the intervention and the end of intervention (6 weeks after the start of intervention). Method of measurement: Blood test.;Serum level of total cholesterol. Timepoint: Before the intervention and the end of intervention (6 weeks after the start of intervention). Method of measurement: Blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRasool Soltani

Esfahan University of Medical Sciences

soltani@pharm.mui.ac.ir+98 31 3786 5537

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026